Hardman Johnston Global Advisors LLC grew its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.9% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 156,567 shares of the company’s stock after buying an additional 1,335 shares during the period. Hardman Johnston Global Advisors LLC’s holdings in Johnson & Johnson were worth $25,577,000 at the end of the most recent reporting period.
Other hedge funds have also made changes to their positions in the company. Rice Partnership LLC raised its stake in shares of Johnson & Johnson by 12.3% during the third quarter. Rice Partnership LLC now owns 53,655 shares of the company’s stock worth $8,765,000 after purchasing an additional 5,868 shares during the last quarter. Aptus Capital Advisors LLC increased its stake in shares of Johnson & Johnson by 7.2% during the third quarter. Aptus Capital Advisors LLC now owns 77,500 shares of the company’s stock worth $12,661,000 after acquiring an additional 5,177 shares during the period. Fagan Associates Inc. raised its holdings in Johnson & Johnson by 0.3% during the third quarter. Fagan Associates Inc. now owns 46,282 shares of the company’s stock worth $7,561,000 after purchasing an additional 145 shares in the last quarter. Summit X LLC lifted its position in Johnson & Johnson by 7.8% in the third quarter. Summit X LLC now owns 3,486 shares of the company’s stock valued at $567,000 after purchasing an additional 252 shares during the period. Finally, Avantax Advisory Services Inc. boosted its holdings in Johnson & Johnson by 3.2% in the 3rd quarter. Avantax Advisory Services Inc. now owns 133,405 shares of the company’s stock valued at $21,793,000 after purchasing an additional 4,134 shares in the last quarter. Institutional investors and hedge funds own 67.94% of the company’s stock.
Wall Street Analyst Weigh In
JNJ has been the subject of several recent analyst reports. Bank of America reduced their price target on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a report on Friday, October 14th. Morgan Stanley decreased their target price on shares of Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating on the stock in a research report on Tuesday, December 6th. Credit Suisse Group started coverage on shares of Johnson & Johnson in a research note on Thursday, November 17th. They issued a “neutral” rating and a $170.00 price objective for the company. Citigroup increased their target price on shares of Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a report on Monday, December 12th. Finally, StockNews.com initiated coverage on Johnson & Johnson in a research note on Wednesday, October 12th. They set a “strong-buy” rating on the stock. Seven research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average target price of $181.75.
Insiders Place Their Bets
Johnson & Johnson Stock Performance
NYSE JNJ opened at $168.31 on Wednesday. The company has a quick ratio of 1.18, a current ratio of 1.43 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The business has a fifty day moving average of $175.98 and a 200-day moving average of $171.06. The stock has a market cap of $440.04 billion, a price-to-earnings ratio of 23.44, a price-to-earnings-growth ratio of 3.21 and a beta of 0.56.
Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, beating the consensus estimate of $2.23 by $0.12. The firm had revenue of $23.71 billion during the quarter, compared to the consensus estimate of $23.90 billion. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The firm’s revenue for the quarter was down 4.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.13 EPS. As a group, analysts predict that Johnson & Johnson will post 10.04 earnings per share for the current fiscal year.
Johnson & Johnson Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be issued a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a dividend yield of 2.69%. The ex-dividend date of this dividend is Friday, February 17th. Johnson & Johnson’s dividend payout ratio (DPR) is 62.95%.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- 3 Retail Stocks Ringing the Register in 2023
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.